Home › Interstitial Lung Diseases › South Carolina
Interstitial Lung Diseases clinical trials in South Carolina
14 studies for Interstitial Lung Diseases are looking for participants at sites in South Carolina.
Cities in South Carolina
FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
- Lowcountry Lung and Critical Care, Charleston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07540988A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
- Medical University of South Carolina, Charleston
RecruitingPhase 3
Ages 40 and older · All sexes · Updated Sep 30, 2026 · NCT07201922LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- MUSC, Charleston
- Velocity Clinical Research, Spartanburg
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Sep 29, 2026 · NCT05798923SUPPORT-T in Patients With Progressive Pulmonary Fibrosis and Their Caregivers
- Medical University of South Carolina, Charleston
Recruiting
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT07269262A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
- Medical University of South Carolina, Charleston
RecruitingPhase 2
Ages 40 and older · All sexes · Updated Sep 4, 2026 · NCT06968845Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
- Medical University of South Carolina, Charleston
Recruiting
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06911632A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
- Clinical Research Site, Charleston
RecruitingPhase 2
Ages 18 to 85 · All sexes · Updated Sep 2, 2026 · NCT07333183DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- AnMed Health, Anderson
- Medical University of South Carolina, Charleston
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 26, 2026 · NCT06388421Platform Clinical Study for Conquering Scleroderma
- Medical University of South Carolina (MUSC), Charleston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT06195072Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
- Medical University of South Carolina, Charleston
RecruitingObservational study
Ages 21 and older · All sexes · Updated Aug 12, 2026 · NCT01915511Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
- Medical University of South Carolina-Nexus, Charleston
- Prisma Health Pulmonology-Richland, Columbia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT05943535An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH
- Medical University of South Carolina, Charleston
RecruitingObservational study
Ages 18 to 80 · All sexes · Updated Jun 26, 2026 · NCT06129240Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
- Bogan Sleep Consultants, LLC, Columbia
RecruitingPhase 2
Ages 40 and older · All sexes · Updated Nov 12, 2025 · NCT05975983Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
- aTyr Investigative Site, Charleston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 7, 2025 · NCT05892614From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.